The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Drug candidates don't usually move among Big Pharma, but these five biotechs helped facilitate such hand-offs, scooping up ...

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Novo Nordisk and Eli Lilly denied weight-loss drug partnership with Mangoceuticals on Thursday, hours after the telehealth ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Lexicon Pharmaceuticals targets a turnaround with sotagliflozin, LX9851, pilavapadin, and partnerships offering multiple ...

Mazur, GM of LillyDirect, breaks down the platform’s new partnership with Walmart and its implications for the pharma ...